Methods for promoting hair growth

Patent metadata

Field	Value
Publication number	US-10166271-B2
Application number	US-76601207-A
Country	US
Kind code	B2
Filing date	Jun 20, 2007
Priority date	Jun 21, 2006
Publication date	Jan 1, 2019
Grant date	Jan 1, 2019

Abstract

This disclosure reveals that cyclic corticotrophin releasing factor (CRF) antagonist peptides (such as astressin B, its functional fragments, and their derivatives) induce hair growth and prevent hair loss in vivo. This important discovery enables, for instance, methods of promoting hair growth, and methods of treating hair loss (such as the hair loss that occurs normally in some individuals or that is the result of a health disorder or therapeutic treatment). Exemplary cyclic CRF antagonist peptides useful in the disclosed methods are provided throughout the disclosure.

First claim

The invention claimed is:

1. A method for promoting hair growth in a subject, comprising:
administering to a subject having a decrease in the number of hair follicles in the anagen phase an effective amount of a cyclic peptide non-selective antagonist of corticotrophin release factor (CRF) receptors 1 and 2 that increases the number of hair follicles in the anagen phase, wherein the antagonist is astressin B and administration is by subcutaneous, intraperitoneal, topical or transdermal delivery;
increasing the number of hair follicles in the anagen phase; and
promoting hair growth in the subject.

2. The method of claim 1 , wherein administering the astressin B comprises topical administration, intraperitoneal injection, intravenous injection, subcutaneous injection, transdermal injection, or intramuscular injection.

3. The method of claim 1 , wherein the astressin B is administered to an area of alopecia-affected skin.

4. The method of claim 1 , wherein the effective amount is from about 1 μg/kg body weight to about 500 μg/kg body weight.

5. The method of claim 1 , wherein the subject is a human.

6. The method of claim 5 , wherein the astressin B is administered to the scalp of the human.

7. The method of claim 1 , wherein the subject is a non-human animal.

8. The method of claim 1 , wherein the decrease in the number of hair follicles in the anagen phase in the subject results from a health disorder or a therapeutic treatment.

9. The method of claim 8 , wherein the health disorder is alopecia areata, traction alopecia, folliculitis alopecia, telogen effluvium, loose-anagen syndrome, toxic alopecia, acquired immune deficiency (AID), hypothyroidism, hyperthyroidism, lupus erythematosus, diabetes, iron deficiency, syphilis, zinc deficiency, trichotillomania, or Cushing syndrome.

10. The method of claim 8 , wherein the therapeutic treatment is chemotherapy or radiation therapy.

11. The method of claim 8 , wherein the therapeutic treatment comprises administration of cyclophosphamide, daunorubicin, doxorubicin, etoposide, ifosamide, paclitaxel, docetaxel, trimethadione, tacrolimus, lithium, atenolol, metoprolol, nadolol, propranolol, timolol, warfarin, heparin, allopurinol, amphetamines, levodopa, bromocriptine and pergolide, pramipexole, ropinerole, vitamin A, isotretinoin, etretinate, tricyclic antidepressants, amphetamines, bupropion, selegeline, clofibrate, gemfibrozil, cimetidine, ranitidine, famotidine, auranofin, indomethacin, naproxen, sulindac, methotrexate, lisinopril, carbimazole, iodine, thiocyanate, or thiouracil.

12. The method of claim 10 , wherein the radiation therapy comprises a dose of radiation less than about 6,000 cGy.

13. The method of claim 1 , wherein administering the astressin B comprises subcutaneous injection.

14. The method of claim 13 , wherein the effective amount is from about 0.1 μg to about 14 mg per injection site.

15. The method of claim 1 , wherein the effective amount is from about 1 μg/kg body weight to about 1000 μg/kg body weight.

16. The method of claim 1 , wherein the effective amount is from about 5 μg to 5 mg of astressin B per dose.

17. The method of claim 1 , wherein the subject has alopecia.

18. A method of preventing hair loss in a subject, comprising:
administering to a subject susceptible to hair loss a therapeutically effective amount of a cyclic peptide non-selective antagonist of corticotrophin release factor (CRF) receptors 1 and 2 that prevents hair loss, wherein the antagonist is astressin B and administration is by subcutaneous, intraperitoneal, topical or transdermal delivery;
assessing hair growth in the subject; and
preventing hair loss in the subject.

19. The method of claim 18 , wherein the subject is at risk for developing alopecia.

Assignees

• Mulugeta Million
• Wang Lixin
• Tache Yvette
• Rivier Jean
• Univ California
• Salk Inst For Biological Studi

Inventors

• Mulugeta Million
• Wang Lixin
• Taché Yvette
• Rivier Jean

Classifications

• A61K38/17 Primary

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61P17/14

  for baldness or alopecia · CPC title